Search Results 591-600 of 18063 for Alopecia

1. IFX_HU2.0 As An Adjunctive Therapy To Pembrolixumab In Checkpoint Inhibitor Naive Subjects With Advanced Or Metastatic Merkel Cell Carcinoma - Mayo Clinic

   ... alopecia) not requiring systemic treatment are permitted to enroll. Low grade autoimmune toxicity is NOT an exclusion under this criterion. Subjects with ...

2. Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Metastatic Colorectal Cancer (OBERTO) - Mayo Clinic

   Relevant toxicities of prior therapies must have resolved, except for oxaliplatin-related neuropathy or alopecia. Anticipated life expectancy ≥6 months ...

3. Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment - Mayo Clinic

   Patient must have recovered to Grade 1 toxicity from prior cancer therapy (a patient with Grade 2 neuropathy or Grade 2 alopecia is an exception to this ...

4. Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy - Mayo Clinic

   Toxicities related to all prior anticancer therapies must have resolved or stabilized, apart from alopecia and peripheral neuropathy. Note: Peripheral ...

5. A Study to Evaluate Safety of Enapotamab Vedotin in Patients with Solid Tumors - Mayo Clinic

   Toxic effects of prior anti-cancer therapy considered as chronic, such as chemotherapy-induced fatigue, alopecia, or anorexia of ≤ Grade 2, where no more ...

6. A Randomized Phase 3 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients with Advanced Angiosarcoma (TAPPAS) - Mayo Clinic

   ... alopecia or neuropathy); Adequate organ function as defined by the following criteria: Serum aspartate transaminase (AST; serum glutamic oxaloacetic ...

7. An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy - Mayo Clinic

   For Part A only: Participants who did not recover from all clinically significant toxicities (excluding alopecia and hematologic toxicities) of any previous ...

8. Romidepsin in Treating Patients with Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors with Liver Dysfunction - Mayo Clinic

   ... alopecia, unless approved by the principal investigator; biologics or immunotherapy will not be allowed within 28 days prior to, or during, romidepsin ...

9. Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer - Mayo Clinic

   Patients who have not recovered from adverse events attributed to prior anti-cancer therapy (i.e. have residual toxicities > grade 1, except for alopecia, ...

10. A Study to Evaluate AVB-S6-500 with Paclitaxel vs Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer - Mayo Clinic

    alopecia. Exclusion Criteria: - Tumors in the breast or bone - Untreated central nervous system (CNS) metastases. Subjects requiring corticosteroid therapy ...